Is HEMO or TILS more profitable?

Tiziana Life Sciences' return on equity of 0.00% beat Hemogenyx Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Hemogenyx Pharmaceuticals N/A -409.57% -37.79% Tiziana Life Sciences N/A N/A N/A

Which has better earnings and valuation, VSN or HEMO?

Hemogenyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Verseon, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Verseon N/A N/A N/A -£14.30 N/A Hemogenyx Pharmaceuticals N/A N/A -£6.89K -£170.60 N/A

Is VSN or HEMO more profitable?

Verseon's return on equity of 0.00% beat Hemogenyx Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Verseon N/A N/A N/A Hemogenyx Pharmaceuticals N/A -409.57% -37.79%

Which has better valuation & earnings, MPH or HEMO?

Hemogenyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Mereo BioPharma Group plc (MPH.L), indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Mereo BioPharma Group plc (MPH.L) N/A N/A N/A -£128.00 N/A Hemogenyx Pharmaceuticals N/A N/A -£6.89K -£170.60 N/A

Is MPH or HEMO more profitable?

Mereo BioPharma Group plc (MPH.L)'s return on equity of 0.00% beat Hemogenyx Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Mereo BioPharma Group plc (MPH.L) N/A N/A N/A Hemogenyx Pharmaceuticals N/A -409.57% -37.79%

Do analysts rate 4BB or HEMO?

4basebio currently has a consensus price target of GBX 1,400, suggesting a potential upside of 154.43%. Given 4basebio's stronger consensus rating and higher probable upside, analysts plainly believe 4basebio is more favorable than Hemogenyx Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 4basebio 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Hemogenyx Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is 4BB or HEMO more profitable?

4basebio's return on equity of -231.29% beat Hemogenyx Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets 4basebio N/A -231.29% -54.30% Hemogenyx Pharmaceuticals N/A -409.57% -37.79%

Does the media favor 4BB or HEMO?

In the previous week, 4basebio had 5 more articles in the media than Hemogenyx Pharmaceuticals. MarketBeat recorded 6 mentions for 4basebio and 1 mentions for Hemogenyx Pharmaceuticals. Hemogenyx Pharmaceuticals' average media sentiment score of 0.37 beat 4basebio's score of 0.10 indicating that Hemogenyx Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 4basebio 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Hemogenyx Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Hemogenyx Pharmaceuticals (HEMO) Competitors

GBX 731 +31.00 (+4.43%)

As of 03:19 AM Eastern

Compare

HEMO vs. TILS, VSN, SCLP, MPH, and 4BB

Should you buy Hemogenyx Pharmaceuticals stock or one of its competitors? Hemogenyx Pharmaceuticals's main competitors and comparable companies include Tiziana Life Sciences (TILS), Verseon (VSN), Scancell (SCLP), Mereo BioPharma Group plc (MPH.L) (MPH), and 4basebio (4BB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Hemogenyx Pharmaceuticals compare to Tiziana Life Sciences?

Hemogenyx Pharmaceuticals (LON:HEMO) and Tiziana Life Sciences (LON:TILS) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.

0.1% of Hemogenyx Pharmaceuticals shares are held by institutional investors. 10.0% of Hemogenyx Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Tiziana Life Sciences has lower revenue, but higher earnings than Hemogenyx Pharmaceuticals. Hemogenyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Tiziana Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hemogenyx Pharmaceuticals	N/A	N/A	-£6.89K	-£170.60	N/A
Tiziana Life Sciences	-£3.60M	0.00	N/A	-£16.30	N/A

In the previous week, Hemogenyx Pharmaceuticals had 1 more articles in the media than Tiziana Life Sciences. MarketBeat recorded 1 mentions for Hemogenyx Pharmaceuticals and 0 mentions for Tiziana Life Sciences. Hemogenyx Pharmaceuticals' average media sentiment score of 0.37 beat Tiziana Life Sciences' score of 0.00 indicating that Hemogenyx Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Hemogenyx Pharmaceuticals	Neutral
Tiziana Life Sciences	Neutral

Tiziana Life Sciences' return on equity of 0.00% beat Hemogenyx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hemogenyx Pharmaceuticals	N/A	-409.57%	-37.79%
Tiziana Life Sciences	N/A	N/A	N/A

Summary

Hemogenyx Pharmaceuticals beats Tiziana Life Sciences on 5 of the 9 factors compared between the two stocks.

How does Hemogenyx Pharmaceuticals compare to Verseon?

Verseon (LON:VSN) and Hemogenyx Pharmaceuticals (LON:HEMO) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, institutional ownership, profitability, media sentiment, risk and dividends.

0.1% of Hemogenyx Pharmaceuticals shares are owned by institutional investors. 10.0% of Hemogenyx Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Verseon's return on equity of 0.00% beat Hemogenyx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verseon	N/A	N/A	N/A
Hemogenyx Pharmaceuticals	N/A	-409.57%	-37.79%

Hemogenyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Verseon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verseon	N/A	N/A	N/A	-£14.30	N/A
Hemogenyx Pharmaceuticals	N/A	N/A	-£6.89K	-£170.60	N/A

In the previous week, Hemogenyx Pharmaceuticals had 1 more articles in the media than Verseon. MarketBeat recorded 1 mentions for Hemogenyx Pharmaceuticals and 0 mentions for Verseon. Hemogenyx Pharmaceuticals' average media sentiment score of 0.37 beat Verseon's score of 0.00 indicating that Hemogenyx Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Verseon	Neutral
Hemogenyx Pharmaceuticals	Neutral

Summary

Hemogenyx Pharmaceuticals beats Verseon on 5 of the 8 factors compared between the two stocks.

How does Hemogenyx Pharmaceuticals compare to Scancell?

Hemogenyx Pharmaceuticals (LON:HEMO) and Scancell (LON:SCLP) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, valuation, risk, media sentiment and analyst recommendations.

In the previous week, Hemogenyx Pharmaceuticals had 1 more articles in the media than Scancell. MarketBeat recorded 1 mentions for Hemogenyx Pharmaceuticals and 0 mentions for Scancell. Hemogenyx Pharmaceuticals' average media sentiment score of 0.37 beat Scancell's score of 0.00 indicating that Hemogenyx Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Hemogenyx Pharmaceuticals	Neutral
Scancell	Neutral

0.1% of Hemogenyx Pharmaceuticals shares are owned by institutional investors. Comparatively, 1.5% of Scancell shares are owned by institutional investors. 10.0% of Hemogenyx Pharmaceuticals shares are owned by insiders. Comparatively, 13.2% of Scancell shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Hemogenyx Pharmaceuticals has higher earnings, but lower revenue than Scancell. Scancell is trading at a lower price-to-earnings ratio than Hemogenyx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hemogenyx Pharmaceuticals	N/A	N/A	-£6.89K	-£170.60	N/A
Scancell	£4.71M	21.31	-£6.75M	-£0.55	N/A

Hemogenyx Pharmaceuticals has a beta of 1.487, indicating that its share price is 49% more volatile than the broader market. Comparatively, Scancell has a beta of 0.685, indicating that its share price is 32% less volatile than the broader market.

Hemogenyx Pharmaceuticals has a net margin of 0.00% compared to Scancell's net margin of -116.98%. Scancell's return on equity of 90.29% beat Hemogenyx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hemogenyx Pharmaceuticals	N/A	-409.57%	-37.79%
Scancell	-116.98%	90.29%	-45.28%

Summary

Hemogenyx Pharmaceuticals beats Scancell on 7 of the 12 factors compared between the two stocks.

How does Hemogenyx Pharmaceuticals compare to Mereo BioPharma Group plc (MPH.L)?

Mereo BioPharma Group plc (MPH.L) (LON:MPH) and Hemogenyx Pharmaceuticals (LON:HEMO) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and institutional ownership.

Mereo BioPharma Group plc (MPH.L)'s return on equity of 0.00% beat Hemogenyx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mereo BioPharma Group plc (MPH.L)	N/A	N/A	N/A
Hemogenyx Pharmaceuticals	N/A	-409.57%	-37.79%

0.1% of Hemogenyx Pharmaceuticals shares are owned by institutional investors. 10.0% of Hemogenyx Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Hemogenyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Mereo BioPharma Group plc (MPH.L), indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mereo BioPharma Group plc (MPH.L)	N/A	N/A	N/A	-£128.00	N/A
Hemogenyx Pharmaceuticals	N/A	N/A	-£6.89K	-£170.60	N/A

In the previous week, Hemogenyx Pharmaceuticals had 1 more articles in the media than Mereo BioPharma Group plc (MPH.L). MarketBeat recorded 1 mentions for Hemogenyx Pharmaceuticals and 0 mentions for Mereo BioPharma Group plc (MPH.L). Hemogenyx Pharmaceuticals' average media sentiment score of 0.37 beat Mereo BioPharma Group plc (MPH.L)'s score of 0.00 indicating that Hemogenyx Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Mereo BioPharma Group plc (MPH.L)	Neutral
Hemogenyx Pharmaceuticals	Neutral

Summary

Mereo BioPharma Group plc (MPH.L) and Hemogenyx Pharmaceuticals tied by winning 4 of the 8 factors compared between the two stocks.

How does Hemogenyx Pharmaceuticals compare to 4basebio?

4basebio (LON:4BB) and Hemogenyx Pharmaceuticals (LON:HEMO) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.

4basebio's return on equity of -231.29% beat Hemogenyx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
4basebio	N/A	-231.29%	-54.30%
Hemogenyx Pharmaceuticals	N/A	-409.57%	-37.79%

Hemogenyx Pharmaceuticals has lower revenue, but higher earnings than 4basebio. 4basebio is trading at a lower price-to-earnings ratio than Hemogenyx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
4basebio	£1.69M	50.33	-£9.84M	-£109.00	N/A
Hemogenyx Pharmaceuticals	N/A	N/A	-£6.89K	-£170.60	N/A

0.9% of 4basebio shares are owned by institutional investors. Comparatively, 0.1% of Hemogenyx Pharmaceuticals shares are owned by institutional investors. 12.1% of 4basebio shares are owned by company insiders. Comparatively, 10.0% of Hemogenyx Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

4basebio currently has a consensus price target of GBX 1,400, suggesting a potential upside of 154.43%. Given 4basebio's stronger consensus rating and higher probable upside, analysts plainly believe 4basebio is more favorable than Hemogenyx Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
4basebio	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Hemogenyx Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, 4basebio had 5 more articles in the media than Hemogenyx Pharmaceuticals. MarketBeat recorded 6 mentions for 4basebio and 1 mentions for Hemogenyx Pharmaceuticals. Hemogenyx Pharmaceuticals' average media sentiment score of 0.37 beat 4basebio's score of 0.10 indicating that Hemogenyx Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
4basebio	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Hemogenyx Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

4basebio has a beta of 1.09, indicating that its stock price is 9% more volatile than the broader market. Comparatively, Hemogenyx Pharmaceuticals has a beta of 1.487, indicating that its stock price is 49% more volatile than the broader market.

Summary

4basebio beats Hemogenyx Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Get Hemogenyx Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HEMO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HEMO vs. The Competition

Export

Metric	Hemogenyx Pharmaceuticals	Biotechnology Industry	Healthcare Sector	LON Exchange
Market Cap	£47.60M	£3.85B	£7.14B	£2.81B
Dividend Yield	N/A	3.65%	2.53%	6.26%
P/E Ratio	-4.10	12.99	274.34	366.69
Price / Sales	N/A	1,347.52	629.40	89,148.58
Price / Cash	2.05	39.04	27.22	27.89
Price / Book	2,841.39	17.06	11.23	6.98
Net Income	-£6.89K	-£23.20M	£3.49B	£5.89B
7 Day Performance	48.15%	-2.14%	-1.31%	-0.67%
1 Month Performance	34.62%	-10.22%	-5.97%	-1.14%
1 Year Performance	-41.25%	17.47%	7.26%	23.00%

Hemogenyx Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HEMO Hemogenyx Pharmaceuticals	N/A	GBX 731 +4.4%	N/A	-35.2%	£49.71M	N/A	N/A	14	Gap Down
TILS Tiziana Life Sciences	N/A	N/A	N/A	N/A	£113.85M	-£3.60M	N/A	11	Positive News
VSN Verseon	N/A	N/A	N/A	N/A	£112.24M	N/A	N/A	N/A	Gap Up
SCLP Scancell	N/A	GBX 9.60 +0.5%	N/A	-3.1%	£102.51M	£4.71M	N/A	51
MPH Mereo BioPharma Group plc (MPH.L)	N/A	N/A	N/A	N/A	£89.76M	N/A	N/A	50	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:HEMO) was last updated on 10/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Hemogenyx Pharmaceuticals (HEMO) Competitors

HEMO vs. TILS, VSN, SCLP, MPH, and 4BB

How does Hemogenyx Pharmaceuticals compare to Tiziana Life Sciences?

Summary

How does Hemogenyx Pharmaceuticals compare to Verseon?

Summary

How does Hemogenyx Pharmaceuticals compare to Scancell?

Summary

How does Hemogenyx Pharmaceuticals compare to Mereo BioPharma Group plc (MPH.L)?

Summary

How does Hemogenyx Pharmaceuticals compare to 4basebio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HEMO vs. The Competition

Hemogenyx Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Hemogenyx Pharmaceuticals (HEMO) Competitors

HEMO vs. TILS, VSN, SCLP, MPH, and 4BB

How does Hemogenyx Pharmaceuticals compare to Tiziana Life Sciences?

Do insiders & institutionals hold more shares of HEMO or TILS?

Which has better valuation and earnings, HEMO or TILS?

Does the media favor HEMO or TILS?

Is HEMO or TILS more profitable?

Summary

How does Hemogenyx Pharmaceuticals compare to Verseon?

Do institutionals & insiders hold more shares of VSN or HEMO?

Is VSN or HEMO more profitable?

Which has better earnings and valuation, VSN or HEMO?

Does the media refer more to VSN or HEMO?

Summary

How does Hemogenyx Pharmaceuticals compare to Scancell?

Does the media refer more to HEMO or SCLP?

Do institutionals & insiders hold more shares of HEMO or SCLP?

Which has preferable valuation & earnings, HEMO or SCLP?

Which has more risk and volatility, HEMO or SCLP?

Is HEMO or SCLP more profitable?

Summary

How does Hemogenyx Pharmaceuticals compare to Mereo BioPharma Group plc (MPH.L)?

Is MPH or HEMO more profitable?

Do institutionals & insiders believe in MPH or HEMO?

Which has better valuation & earnings, MPH or HEMO?

Does the media refer more to MPH or HEMO?

Summary

How does Hemogenyx Pharmaceuticals compare to 4basebio?

Is 4BB or HEMO more profitable?

Which has better valuation and earnings, 4BB or HEMO?

Do insiders and institutionals hold more shares of 4BB or HEMO?

Do analysts rate 4BB or HEMO?

Does the media favor 4BB or HEMO?

Which has more volatility and risk, 4BB or HEMO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HEMO vs. The Competition

Hemogenyx Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools